Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
FibroGen and AstraZeneca have been unable to find a path forward for the drug in that indication.
Source: https://medcitynews.com/2023/06/fibrosis-drug-clinical-trial-failure-fibrogen/
Finally, Stifel Nicolaus raised shares of FibroGen from a “hold” rating to a “buy” rating and increased their price target for the company from $23.00 to $32.00 in a research report on Thursday, June 1st.
I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen.